quinoxalines has been researched along with Leishmaniasis, American in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (66.67) | 24.3611 |
2020's | 1 (33.33) | 2.80 |
Authors | Studies |
---|---|
Auzely-Velty, R; Corrêa, AG; de Oliveira, JK; Lopez, RFV; Nakamura, CV; Petrilli, R; Ueda-Nakamura, T | 1 |
Bastien, P; Bonnet, PA; Bou Youness, H; El Hajj, H; El Hajj, R; Khalifeh, I; Lachaud, L; Masquefa, C | 1 |
Barbi, J; Cummings, HE; Keiser, TL; Lezama-Davila, C; Lu, B; Oghumu, S; Radzioch, D; Reville, P; Rommel, C; Rückle, T; Sarkar, A; Satoskar, AR; Seveau, S; Varikuti, S; Wewers, MD; Whitacre, C; Zorko, N | 1 |
3 other study(ies) available for quinoxalines and Leishmaniasis, American
Article | Year |
---|---|
Liposome-based nanocarrier loaded with a new quinoxaline derivative for the treatment of cutaneous leishmaniasis.
Topics: Animals; Chlorocebus aethiops; Leishmania; Leishmaniasis, Cutaneous; Liposomes; Male; Mice; Mice, Hairless; Nanoparticles; Quinoxalines; Vero Cells | 2020 |
EAPB0503: An Imiquimod analog with potent in vitro activity against cutaneous leishmaniasis caused by Leishmania major and Leishmania tropica.
Topics: Humans; Imiquimod; Leishmania major; Leishmania tropica; Leishmaniasis, Cutaneous; NF-kappa B; Quinoxalines; Syria; Toll-Like Receptors | 2018 |
Critical role for phosphoinositide 3-kinase gamma in parasite invasion and disease progression of cutaneous leishmaniasis.
Topics: Animals; Antimony Sodium Gluconate; Disease Resistance; Flow Cytometry; Host-Parasite Interactions; Humans; Leishmania mexicana; Leishmaniasis, Cutaneous; Macrophages; Mice; Mice, Inbred C57BL; Microscopy, Fluorescence; Neutrophils; Phagocytes; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Quinoxalines; Thiazolidinediones | 2012 |